{"disease":{"id":"vitiligo","name":"Vitiligo","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":1,"trial_count":7},"drugs":{"marketed":[{"drug_id":"ruxolitinib","indication_name":"Vitiligo","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jakafi","generic_name":"RUXOLITINIB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Ankyrin repeat and protein kinase domain-containing protein 1, Bone morphogenetic protein receptor type-1B, Calcium/calmodulin-dependent protein kinase type IV","drug_class":"","quality_score":null,"revenue":"2600","mechanism":null},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Cultured Autologous Tissue-Engineered Skin Substitute for the Treatment of Vitiligo","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"trioxsalen","indication_name":"Vitiligo","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trisoralen","generic_name":"TRIOXSALEN","company_name":"","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Psoralen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe vitiligo","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe vitiligo in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"methoxsalen","indication_name":"Vitiligo","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxsoralen-Ultra","generic_name":"METHOXSALEN","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Cytochrome P450 1A2","drug_class":"Photoactivated Radical Generator [EPC]","quality_score":65,"revenue":null,"mechanism":"Oxsoralen-Ultra works by generating free radicals when exposed to ultraviolet A (UVA) light, which helps to slow down the growth of skin cells and reduce inflammation."},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Cultured Autologous Melanocytes for the Treatment of Vitiligo","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"pf-07038124","indication_name":"Vitiligo","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07038124","generic_name":"pf-07038124","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Phosphodiesterase-4 (PDE4)","drug_class":"Phosphodiesterase-4 inhibitor","quality_score":25,"revenue":null,"mechanism":"PF-07038124 is a topical PDE4 inhibitor that blocks phosphodiesterase-4 to reduce inflammatory cytokine production in skin immune cells."}],"offLabel":[],"totalMarketed":7,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT04969419","title":"Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo","phase":"","overall_status":"COMPLETED","enrollment_count":75771,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT06097494","title":"Investigating Healthcare Disparities in Vitiligo","phase":"","overall_status":"COMPLETED","enrollment_count":39374,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT04953338","title":"Mental Health Associations With Vitiligo","phase":"","overall_status":"COMPLETED","enrollment_count":36104,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT05084417","title":"A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"OM1, Inc.","has_results":false},{"nct_id":"NCT06072183","title":"A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1571,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04039451","title":"Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05968235","title":"Correlation of Glucose and Lipid Metabolism Levels With Vitiligo","phase":"","overall_status":"COMPLETED","enrollment_count":963,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT05583526","title":"A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":607,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03323125","title":"Photoprotection Habits in Patients With Vitiligo","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06113445","title":"A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":467,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT04530344","title":"Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":458,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06113471","title":"A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03976622","title":"Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata","phase":"","overall_status":"UNKNOWN","enrollment_count":450,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06163326","title":"A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06801821","title":"Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06877000","title":"Vitiligo Severity, Quality of Life, Work Productivity and Activity Impairment","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT03715829","title":"A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":366,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04057573","title":"Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":344,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04052425","title":"Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":330,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04487860","title":"Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":327,"lead_sponsor_name":"Ache Laboratorios Farmaceuticos S.A.","has_results":true},{"nct_id":"NCT03622320","title":"Metabolic Syndrome in Early Onset Versus Late Onset Vitiligo","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT06324695","title":"Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin disEases","phase":"NA","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT04789993","title":"Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT06804811","title":"A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT07046039","title":"The Impact of Untreated Depression and Anxiety Among Patients With Skin Diseases in Jeddah, Saudi Arabia.","phase":"","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"King Abdulaziz University","has_results":false},{"nct_id":"NCT07431177","title":"A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03608917","title":"Efficacy and Safety of Total Glucosides of Paeony Combined With NB-UVB on Treating Vitiligo","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"xjpfW","has_results":false},{"nct_id":"NCT06493578","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":false},{"nct_id":"NCT07108283","title":"A Study of Zasocitinib in Adults With Nonsegmental Vitiligo","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT04927975","title":"Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":185,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT06548360","title":"A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT04734704","title":"Defining the Role of the Skin Microbiome in Immune-related Adverse Events","phase":"NA","overall_status":"UNKNOWN","enrollment_count":175,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT04818346","title":"A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":171,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT07153666","title":"A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo","phase":"","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT06113328","title":"A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":169,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03099304","title":"A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":157,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT07181187","title":"Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":156,"lead_sponsor_name":"Minghui Pharmaceutical (Hangzhou) Ltd","has_results":false},{"nct_id":"NCT07509242","title":"Comparative Efficacy of hUCMSC-Secretome Delivered Via Microneedling and Intradermal Microinjection as Adjuvant Therapy to NB-UVB in Nonsegmental Vitiligo: A Quasi-Experimental Study","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Yohanes Firmansyah, dr, MH, MM","has_results":false},{"nct_id":"NCT04811326","title":"Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Shaimaa Fawzy Abdel-rady Abdel-latif","has_results":false},{"nct_id":"NCT06511739","title":"A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"CSPC Ouyi Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06327321","title":"Vitiligo Treatment by Targeting TYK2 Mediated Responses","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT07298551","title":"Building an Assessment Model for Vitiligo Activity and Prognosis Using Peripheral Blood Cytokine Profiles","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":125,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT05098600","title":"The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","phase":"","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Faculty Hospital Kralovske Vinohrady","has_results":false},{"nct_id":"NCT07172347","title":"Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Jiangsu vcare pharmaceutical technology co., LTD","has_results":false},{"nct_id":"NCT07368673","title":"Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Dow University of Health Sciences","has_results":false},{"nct_id":"NCT03941184","title":"Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04811131","title":"Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":114,"lead_sponsor_name":"Arcutis Biotherapeutics, Inc.","has_results":true},{"nct_id":"NCT05836441","title":"Improved Phototherapy in Patients With Vitiligo","phase":"NA","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT05971381","title":"Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells","phase":"NA","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Avita Medical","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}